Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jul;153(3):425-440.
doi: 10.1007/s11060-021-03777-9. Epub 2021 Jun 2.

What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

Jihane Adelon  1 , Christelle Dufour  2 , Stéphanie Foulon  3 , Julien Masliah Planchon  4 , David Meyronnet  5 , Franck Bourdeaut  6 , Gilles Palenzuela  7 , Fanny Fouyssac  8 , Sandra Raimbault  9 , Emilie De Carli  10 , Sébastien Klein  11 , Anne Pagnier  12 , Anne-Isabelle Bertozzi  13 , Angélique Rome  14 , Audrey David  15 , Sylvie Chabaud  16 , Cécile Faure-Conter  17
Affiliations
Multicenter Study

What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

Jihane Adelon et al. J Neurooncol. 2021 Jul.

Abstract

Purpose: High-risk medulloblastomas (HR-MB) may not respond to induction chemotherapy, with either post-induction stable (SD) or progressive disease (PD). There is no consensus regarding their optimal management.

Methods: A retrospective, multicentre study investigated patients with non-responder HR-MB treated according to the PNET HR + 5 protocol (NCT00936156) between 01/01/2009 and 31/12/2018. After two courses of etoposide and carboplatin (induction), patients with SD or PD were analyzed. Upon clinician's decision, the PNET HR + 5 protocol was either pursued with tandem high-dose chemotherapy (HDCT) and craniospinal irradiation (CSI) (continuation group) or it was modified (switched group).

Results: Forty-nine patients were identified. After induction, 37 patients had SD and 12 had PD. The outcomes were better for the SD group: the 5-y PFS and OS were 52% (95% CI 35-67) and 70% (95% CI 51-83), respectively, in the SD group while the 2-y PFS and OS were 17% (95% CI 3-41) and 25% (95% CI 6-50), respectively, in the PD group (p < 0.0001). The PNET HR + 5 strategy was pursued for 3 patients in the PD group, of whom only one survived. In the SD group, it was pursued for 24/37 patients whereas 13 patients received miscellaneous treatments including a 36 Gy CSI in 12 cases. Despite that continuation and switched group were well-balanced for factors impacting the outcomes, the latter were better in the continuation group than in the switched group: the 5-y PFS were 78% (95% CI 54-90) versus 0% (p < 0.001), and the 5-y OS were 78% (95% CI 54-90) versus 56% (95% CI 23-79) (p = 0.0618) respectively. In the SD group, multivariate analysis revealed that MYC amplification, molecular group 3, and a switched strategy were independent prognostic factors for progression.

Conclusion: Patients with post-induction SD may benefit from HDCT and CSI, whereas patients with early PD will require new therapeutic approaches.

Keywords: High-dose chemotherapy; survival-relapse; High-risk pediatric medulloblastomas; Stable disease -progressive disease.

PubMed Disclaimer

References

    1. Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl) 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1 - DOI
    1. Chang CH, Housepian EM, Herbert C (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93(6):1351–1359. https://doi.org/10.1148/93.6.1351 - DOI - PubMed
    1. Dufour C, Foulon S, Geoffray A et al (2020) Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5. Neuro-Oncol. https://doi.org/10.1093/neuonc/noaa301 - DOI - PubMed - PMC
    1. Taylor RE, Bailey CC, Robinson KJ et al (2005) Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer Oxf Engl. 41(5):727–734. https://doi.org/10.1016/j.ejca.2004.12.017 - DOI
    1. Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820. https://doi.org/10.1016/S1470-2045(06)70867-1 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources